인쇄하기
취소

Green Cross to conduct Phase I trial for DNA recombinant product

Published: 2008-03-27 06:57:00
Updated: 2008-03-27 06:57:00
Green Cross Corporation plans to carry out its Phase I study to evaluate a new DNA recombinant drug Hepabig-Gene, which was approved by the Korean Food and Drug Administration.

The Phase I study for Hepabig-Gene is an open, comparative, increased dose clinical trial at the general surgery department of the Seoul Asan Hospital, where pharmacokinetics and safety profiles will be reviewed when ...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.